Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages

Table 2 Currently approved immune checkpoint inhibitors

Drug name	Trade name	Target	Manufacturer	Age	Indication	References
Ipilimumab	Yervoy®	CTLA-4	Bristol-Meyers Squibb	2011	Melanoma, RCC	[77]
Nivolumab	Opdivo®	PD-1	Bristol-Meyers Squibb	2015	Melanoma, RCC, NSCLC, HNSCC, HL, Urothelial carcinoma, HCC, Colorectal cancer	[81]
Pembrolizumab	Keytruda®	PD-1	Merck	2014	Melanoma, NSCLC, HNSCC, PMBCL HL, Urothelial carcinoma, HCC, Cervical cancer, Gastric cancer, MSI-H/dMMR Solid Tumors	[82]
Cemiplimab-rwlc	Libtayo®	PD-1	Sanofi/ Regeneron	2018	CSCC, BCC, NSCLC	[88]
Atezolizumab	Tecentriq™	PD-L1	Genentech	2016	Urothelial carcinoma, NSCLC	[90]
Durvalumab	Imfinzi™	PD-L1	Astra Zeneca	2017	Urothelial carcinoma, NSCLC	[92]
Avelumab	Bavencio®	PD-L1	Merck/Pfizer	2017	Merkel cell carcinoma, RCC, Urothelial carcinoma	[97]

RCC renal cell cancer, NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell carcinoma, HCC hepatocellular carcinoma, HL Hodgkin lymphoma(classic), PMBCL primary mediastinal B cell lymphoma, MSI-H microsatellite instability-high, dMMR mismatch repair gene-deficient, CSCC Cutaneous Squamous Cell Carcinoma, BCC Basal Cell Carcinoma

ISSN: 1475-2867